Devonian Health Group Inc. announced that results from phase 2 clinical study in mild-to-moderate atopic dermatitis (``AD'') will be presented at the upcoming 25th World Congress of Dermatology (``WCD'') to be held in Singapore from July 3rd to 8th. Results from the study will be made available on Devonian's website following the poster presentation at WCD by Dr. Charles Lynde (Associate Professor, University of Toronto, Department of Medicine). Poster: Phase 2 trial of a Novel Botanical Topical Anti-Inflammatory Drug, in adults with Mild-to-Moderate Atopic Dermatitis.

This poster summarizes results from the phase 2 clinical study in adult patients with mild-to-moderate atopic dermatitis. In the study, the efficacy of ThykamineTM cream was comparable to other non-steroidal topical therapies approved for the treatment of mild-to-moderate AD, while demonstrating a favorable safety and tolerability profile. ThykamineTM Clinical Development Program Update Devonian also provided an update on its ThykamineTM program activities in advance of the WCD Meeting.

To support the clinical program of ThykamineTM, the company is establishing its final formulation manufacturing activities in a leading global contract development and manufacturing. The transfer and validation process should be completed within the next months. Devonian will then, as a priority, file to regulatory agencies a phase 2/3 protocol in pediatric patient population with mild-to-moderate atopic dermatitis.

As second and third priorities, the corporation expects to file a phase2 clinical study protocol in radiodermatitis associated to radiotherapy and a phase 2 clinical study in Hand and Foot Syndrome associated to chemotherapy.